Cipla Limited — Important, 27-07-2026: Updates

Cipla secured US FDA approval for its generic Advair Diskus®, a key therapy for asthma/COPD. The US market for this product is ~$908 million. Expected launch is Q2 FY27. This marks Cipla's first US-made dry powder inhaler approval, significantly boosting its respiratory capabilities and market presence.